Bridges Investment Management Inc. Invests $487,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bridges Investment Management Inc. purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 6,069 shares of the medical equipment provider’s stock, valued at approximately $487,000.

Several other large investors have also recently added to or reduced their stakes in LNTH. Farallon Capital Management LLC increased its position in Lantheus by 595.3% during the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock worth $92,316,000 after purchasing an additional 1,269,900 shares during the period. Norges Bank purchased a new position in Lantheus in the fourth quarter worth $29,956,000. Swedbank AB acquired a new stake in Lantheus in the first quarter valued at $26,346,000. Nomura Holdings Inc. boosted its position in shares of Lantheus by 105.3% during the 4th quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider’s stock worth $1,282,000 after purchasing an additional 407,507 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its stake in shares of Lantheus by 25.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock worth $121,867,000 after purchasing an additional 394,837 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. Truist Financial lowered their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. JMP Securities reduced their price objective on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. B. Riley upped their target price on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Finally, Leerink Partners boosted their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Lantheus Trading Up 1.4 %

Shares of LNTH stock opened at $110.05 on Friday. The company has a market capitalization of $7.63 billion, a price-to-earnings ratio of 16.80 and a beta of 0.50. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average price of $105.51 and a 200 day moving average price of $84.24. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business’s quarterly revenue was up 22.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.40 EPS. Research analysts forecast that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction on Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the transaction, the chief accounting officer now owns 62,216 shares in the company, valued at approximately $7,661,900.40. The disclosure for this sale can be found here. Insiders have sold 40,852 shares of company stock worth $3,922,001 over the last quarter. 1.50% of the stock is currently owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.